Ovarian neoplasms are a heterogeneous group of tumours classified according
to morphological and clinical features. The main subgroups are:
epithelial tumours
sex cord – stromal tumours
germ cell tumours
miscellaneous and metastatic tumours.
The majority of ovarian tumours (59% of all ovarian tumours and up to 90%
of all primary ovarian malignancies) are epithelial. Epithelial tumours can
be further classified as follows:
serous
mucinous
endometrioid
mixed mesodermal / carcinosarcoma
clear cell
transitional cell
mixed epithelial
undifferentiated carcinomas.
The most common tumours are serous and mucinous lesions.
Mixed mesodermal tumours are now considered to be carcinomas with areas of
sarcomatous differentiation.
A benign tumour has no abnormal cytological or proliferative
features and no evidence of stromal invasion. There is no significant
malignant
potential.
A borderline (low malignant potential or atypically
proliferating) tumour is a lesion which has abnormal cytological and proliferative
features
within its epithelium but which has no evidence of invasion into the stromal
supporting tissues. Extraovarian disease can occur and these tumour deposits
are referred to as implants. Non-invasive implants are associated with
a good prognosis. Invasive implants are associated with a prognosis that
is intermediate
between those of benign and malignant tumours. Most borderline tumours
present as stage I lesions and are cured by surgery. Stage by stage the
overall survival
of women with borderline tumours is superior to women with epithelial ovarian
cancer.
A malignant tumour is present when there is evidence
of invasion into the stromal tissues of the ovary. This is usually associated
with cytological atypia and increased proliferative activity. Invasion
is best defined as the presence of irregular spiculated or ragged epithelial
islands with individual cells extending into the stromal tissues. These
stromal tissues can display reactive changes such as necrosis or an immature
fibroblastic
response. These cytological and proliferative changes can occur focally
within the ovarian mass. An ovarian tumour must be adequately sampled
for histological
examination.
Primary peritoneal cancer is a tumour which shows similar
morphological characteristics toovarian cancer but which has no or minimal
ovarian involvement.
GRADING OF OVARIAN CANCER
There is no single universally accepted system for grading ovarian cancers.
Many studies have used different systems proposed either by FIGO or WHO or
the
American Gynecologic Oncology Group (GOG). A newly proposed grading system,
based on the Nottingham system of breast cancer grading, assesses the architectural
pattern of the ovarian tumour, cytological atypia and the mitotic activity
within the tumour.179,
180, 181
The FIGO staging system described in Annex 1 is a surgical staging system
which does not incorporate the grade of the tumour.
PSEUDOMYXOMA PERITONEI
Pseudomyxoma peritonei is a clinical condition characterised by
the presence of mucinous material within the peritoneal cavity. This condition
may
originate from either the ovary or gastrointestinal tract. In gynaecological
pathology it is more often seen in association with borderline mucinous ovarian
tumours. In view of the debate about the primary site of origin of these
tumours the appendix should be examined. Pathological examination of the mucinous
material
and associated tissues should specify whether epithelial cells are present
or not. The cytological characteristics of the cells should also be described.
BRAC1 AND BRAC2
BRCA1, a gene on chromosome 17 and BRCA2, a gene on chromosome 13, increase
susceptibility to breast and ovarian cancer.